Cytology Assessment Can Predict Survival for Patients With Metastatic Pancreatic Neuroendocrine Neoplasms

被引:11
|
作者
Sigel, Carlie S. [1 ]
Guo, Huimin [1 ]
Sigel, Keith M. [2 ]
Zhang, Ming [1 ]
Rekhtman, Natasha [1 ]
Lin, Oscar [1 ]
Klimstra, David S. [1 ]
Jungbluth, Achim A. [1 ]
Tang, Laura K. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA
[2] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
cytology; grade; differentiation; Ki-67; index; metastatic; neuroendocrine carcinoma; pancreas; pancreatic neuroendocrine tumor; HIGH-GRADE; LABELING INDEX; TUMORS; CARCINOMAS; DISTINCT; CELL;
D O I
10.1002/cncy.21817
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Histological features and Ki-67 index have known usefulness in predicting prognosis and guiding therapy among patients with metastatic pancreatic neuroendocrine neoplasms. Fine-needle aspiration may offer advantages for Ki-67 assessment because the technique obtains highly cellular, well-preserved specimens with the potential for broader tumor sampling. In the current study, the authors evaluated concordance for grade and differentiation between concurrent core needle biopsy and cytology preparations. Cytological features and grade then were correlated with survival. METHODS: Differentiation, grade by Ki-67 index, and correlation of these features with survival were compared between concurrent core needle biopsy and cytology specimens from 44 patients with metastatic pancreatic neuroendocrine neoplasms. RESULTS: Differentiation by cytology smear resulted in 38 cases of well (86%) and 6 cases of poor (14%) differentiation. Agreement for differentiation between smear and cell block, smear and core needle biopsy, and cell block and core needle biopsy was 88%, 94%, and 83%, respectively, and agreement for grade was 68%, 54%, and 22%, respectively. Cytology differentiation and cytology grade were found to be strong predictors of outcome with respective hazard ratios of 8.3 (95% confidence interval [95% CI], 3.1-22.1; P<.001) and 1.9 (95% CI, 1.2-2.9) for each ascending grade. The median disease-specific survival cytology projections were 121 months (95% CI, 57-185 months [estimated]) for grade 1, 45 months (95% CI, 29-87 months) for grade 2, and 19 months (95% CI, 1-44 months) for grade 3, with median survivals of 45 months and 3 months, respectively, for patients with well-differentiated and poorly differentiated neuroendocrine tumors (P<. 001). CONCLUSIONS: Grading of pancreatic neuroendocrine neoplasms on cytology may not correlate exactly with concurrent core needle biopsy, but cytology differentiation and grade are predictive of survival based on stage-adjusted analysis. (C) 2017 American Cancer Society.
引用
收藏
页码:188 / 196
页数:9
相关论文
共 50 条
  • [21] Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?
    Pak, Linda M.
    Gonen, Mithat
    Seier, Kenneth
    Balachandran, Vinod P.
    D'Angelica, Michael I.
    Jarnagin, William R.
    Kingham, T. Peter
    Allen, Peter J.
    Do, Richard K. G.
    Simpson, Amber L.
    ABDOMINAL RADIOLOGY, 2018, 43 (08) : 2113 - 2118
  • [22] Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?
    Linda M. Pak
    Mithat Gonen
    Kenneth Seier
    Vinod P. Balachandran
    Michael I. D’Angelica
    William R. Jarnagin
    T. Peter Kingham
    Peter J. Allen
    Richard K. G. Do
    Amber L. Simpson
    Abdominal Radiology, 2018, 43 : 2113 - 2118
  • [23] Assessment of the Role of Leptin and Adiponectinas Biomarkers in Pancreatic Neuroendocrine Neoplasms
    Bocian-Jastrzebska, Agnes
    Malczewska-Herman, Anna
    Rosiek, Violetta
    Kos-Kudla, Beata
    CANCERS, 2023, 15 (13)
  • [24] A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms
    Zhang, Sheng
    Tong, Yi Xin
    Zhang, Xin Hua
    Zhang, Yu Jie
    Xu, Xiang Shang
    Xiao, Ai Tang
    Chao, Teng Fei
    Gong, Jian Ping
    JOURNAL OF CANCER, 2019, 10 (24): : 5944 - 5954
  • [25] Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms
    Yu, Fei
    Fu, Jingjing
    Zhang, Chuan
    Wu, Wenyu
    Ai, Shuyue
    Yao, Xiaochen
    Meng, Qingle
    Huang, Yue
    Lu, Guangming
    Wang, Feng
    Qu, Wei
    PANCREAS, 2021, 50 (06) : 882 - 889
  • [26] The patterns of metastatic disease and survival in patients with pancreatic neuroendocrine tumours: a retrospective observational study
    Wong, T.
    Buddle, E.
    Jaffer, R.
    Adiamah, A.
    Murugan, V.
    Wong, Z.
    Lobo, D. N.
    BRITISH JOURNAL OF SURGERY, 2023, 110
  • [27] The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma
    Mohammed, Amrallah A.
    Al-Zahrani, Omar
    Elsayed, Fifi Mostafa
    INDIAN JOURNAL OF PALLIATIVE CARE, 2022, 28 (04) : 406 - 412
  • [28] Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?
    Jayavalsan, Shinoj Pattali
    Schmidt, Shannon Leah
    Durkal, Vipal
    Ritch, Paul S.
    Thomas, James P.
    Erickson, Beth
    Christians, Kathleen K.
    Tsai, Susan
    Evans, Douglas B.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] Nomograms predict survival outcomes for distant metastatic pancreatic neuroendocrine tumor A population based STROBE compliant study
    Li, Gang
    Tian, Mao-lin
    Bing, Yun-tao
    Wang, Hang-yan
    Yuan, Chun-hui
    Xiu, Dian-rong
    MEDICINE, 2020, 99 (13) : E19593
  • [30] Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms
    Diebold, Anne E.
    Boudreaux, J. Philip
    Wang, Yi-Zarn
    Anthony, Lowell B.
    Uhlhorn, Ann Porter
    Ryan, Pamela
    Marnikunian, Paris
    Mainikimian, Gregg
    Woltering, Eugene A.
    SURGERY, 2012, 152 (06) : 1172 - 1176